Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04913337 · ClinicalTrials.gov registry record · Phase 1
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NGM Biopharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 179
- Enrollment target
- 20
- Study locations
NCT04913337: Active Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NGM Biopharmaceuticals.
NCT04913337 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by NGM Biopharmaceuticals. The registered enrollment target is 179 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04913337, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by NGM Biopharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 179 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Conditions Studied
Interventions
- DRUG NGM707
- DRUG NGM707 plus pembrolizumab (KEYTRUDA®)
Study Locations (20)
Texas
- NGM Clinical Study Site - Dallas
- NGM Clinical Study Site - Dallas
- NGM Clinical Study Site - Houston
- NGM Clinical Study Site - San Antonio
- NGM Clinical Study Site - San Antonio
California
- NGM Clinical Study Site - Los Angeles
- NGM Clinical Study Site - Newport Beach
- NGM Clinical Study Site - Santa Monica
- NGM Clinical Study Site - Santa Rosa
Colorado
- NGM Clinical Study Site - Lone Tree
District of Columbia
- NGM Clinical Study Site - Washington D.C.
Florida
- NGM Clinical Study Site - Sarasota
Maryland
- NGM Clinical Study Site - Baltimore
Massachusetts
- NGM Clinical Study Site - Boston
Michigan
- NGM Clinical Study Site - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2025-07 |
| Phase | Phase 1 |
What the registry record for NCT04913337 still lists
NCT04913337 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which NGM707 is the first listed.
NCT04913337 names 20 study sites across 13 states, led by Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04913337 about?
NCT04913337 is a clinical study titled "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies". Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
What is the current status of trial NCT04913337?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2021-06-09. Estimated completion is 2025-07.
What conditions does trial NCT04913337 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Glioblastoma, Gastric Cancer.
What interventions are being tested in trial NCT04913337?
The interventions under investigation include: NGM707 (DRUG), NGM707 plus pembrolizumab (KEYTRUDA®) (DRUG).
Who is sponsoring clinical trial NCT04913337?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04913337 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04913337's enrollment target sits among peer trials
179 409th of 1224 higher than 816 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI